Verastem announced it received FDA Breakthrough Therapy designation for VS-6766 with defactinib in recurrent low-grade serous ovarian cancer.
If the flag holds, it looks like it could hit around $4.60. Considering adding to my position today. But probably will just hold with what I have.
If the flag holds, it looks like it could hit around $4.60. Considering adding to my position today. But probably will just hold with what I have.